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Summary
Survival during prolonged food deprivation depends on the activation of hepatic gluconeogenesis. Inappropriate regulation
of this process is a hallmark of diabetes and other metabolic diseases. Activation of the genes encoding gluconeogenic
enzymes is mediated by hormone-responsive transcription factors such as the cyclic AMP response element binding
protein (CREB) and the glucocorticoid receptor (GR). Here we show using cell-type-specific gene ablation that the winged
helix transcription factor Foxa2 is required for activation of the hepatic gluconeogenic program during fasting. Specifically,
Foxa2 promotes gene activation both by cyclic AMP, the second messenger for glucagon, and glucocorticoids. Foxa2
mediates these effects by enabling recruitment of CREB and GR to their respective target sites in chromatin. We conclude
that Foxa2 is required for execution of the hepatic gluconeogenic program by integrating the transcriptional response of
the hepatocyte to hormonal stimulation.Introduction
Mammals have evolved complex systems to maintain blood
glucose levels within a narrow range even when food supply is
limited. The liver is the major provider of glucose in times of
food restriction, initially through mobilization of glycogen and
in the long term by de novo synthesis of glucose, or gluconeo-
genesis. Red blood cells and the brain are dependent on glu-
cose as metabolic fuel, and severe reductions in blood glucose
may result in seizures or death. The enzymes required for he-
patic gluconeogenesis are regulated at the transcriptional level,
with multiple transcription factors cooperating to ensure the
appropriate adaptations to the metabolic and hormonal status
of the organism. In response to fasting, blood insulin levels
drop, while glucagon and glucocorticoid levels rise, promoting
hepatic gluconeogenesis through activation of the cAMP re-
sponse element binding protein (CREB) and the glucocorticoid
receptor (GR), respectively. A long-standing paradox has been
the fact that both CREB and GR are expressed in multiple or-
gans, yet the activation of the gluconeogenic program occurs
primarily in the liver and to a lesser extent in the kidney (Han-
son and Reshef, 1997). Analysis of cis-regulatory elements of
genes encoding gluconeogenic enzymes has led to the finding
that binding sites for CREB and GR are often located in close
proximity to those of nuclear factors expressed predominantly
in hepatocytes, including hepatocyte nuclear factor 4α (HNF-
4α) and the Foxa (also known as HNF-3) proteins (Lucas and
Granner, 1992; Nitsch et al., 1993; Nitsch and Schutz, 1993;
Wang et al., 1996). However, the requirement for the Foxa fac-
tors in hormone-dependent activation of the hepatic gluco-
neogenic program has not been investigated by genetic means
in vivo until now. Here we utilize tissue-specific gene ablation
of Foxa2 in hepatocytes to demonstrate a requirement for this
factor in the hepatic response to a prolonged fast.CELL METABOLISM : AUGUST 2005 · VOL. 2 · COPYRIGHT © 2005 ELSResults
Derivation of mice deficient for Foxa2 in hepatocytes
As embryos lacking Foxa2 die in midgestation due to an essen-
tial role for Foxa2 in the formation of the node and notochord
(Ang and Rossant, 1994; Weinstein et al., 1994), we employed
cell-type-specific gene ablation to delete the gene only in he-
patocytes. Using a loxP-flanked allele of Foxa2 (Foxa2loxP) and
a transgene in which expression of Cre is dependent on the
albumin promoter and the α-fetoprotein enhancer (AlfpCre), the
Foxa2 gene was deleted quantitatively in the liver (Figures 1A
and 1B). To evaluate potential regulatory relationships among
the Foxa genes, which might result in partial compensation, we
determined the mRNA levels of the two closely related genes,
Foxa1 and Foxa3. While Foxa3 expression is not dependent on
Foxa2, Foxa1 mRNA expression was increased by about 70%
(Figure 1C), consistent with the presence of a Foxa binding
site in the Foxa1 promoter described previously (Peterson et
al., 1997).
Foxa2 is required for the induction of hepatic gene
expression in response to fasting
To investigate how Foxa2 regulates the hepatic response to
fasting, we chose to evaluate the expression of three represen-
tative genes that are exquisitely sensitive to hormonal regu-
lation (Hanson and Reshef, 1997; Lucas and Granner, 1992;
Unterman et al., 1994): PEPCK (phosphoenolpyruvate car-
boxykinase), the rate-limiting enzyme in gluconeogenesis; TAT
(tyrosine aminotransferase), and IGFBP-1 (insulin growth factor
binding protein 1). Concordant with previous findings, expres-
sion of all three genes is robustly induced by a prolonged fast
in wild-type mice (Figures 2A–2C). However, activation of these
genes is blunted significantly in the absence of Foxa2. TheseEVIER INC. DOI 10.1016/j.cmet.2005.07.002 141
S H O R T A R T I C L EFigure 1. Foxa2 is deleted efficiently in Foxa2loxP/loxP;
AlfpCre mice
A) Immunofluorescence staining of wild-type liver
with a monospecific antibody to Foxa2 demon-
strates nuclear localization of Foxa2.
B) Foxa2 is quantitatively deleted in hepatocytes
from Foxa2loxP/loxP; AlfpCre mice.
C) Quantitative reverse transcription PCR analysis
confirms absence of Foxa2 expression in livers from
Foxa2loxP/loxP; AlfpCre mice and shows a 70% in-
crease in Foxa1 expression. Black bars, control
mice. White bars, Foxa2loxP/loxP; AlfpCre mice. Error
bars are standard error of the mean (SEM).results clearly demonstrate that Foxa2 is required for the full
activation of the hepatic transcriptional response to fasting.
Foxa2 is required for full stimulatory activity of both
glucocorticoid and cAMP signaling
The shift from the fed to the fasted state results in induction of
complex hormonal responses, with the activation of the hypo-
thalamic-pituitary-adrenal axis resulting in the elevation of glu-
cocorticoid levels, and a switch in the endocrine pancreas from
the release of insulin to glucagon. In order to define the specific
contribution of Foxa2 in this complex in vivo process, we iso-
lated primary hepatocytes and cultured them in a three-dimen-
sional collagen matrix to assess responsiveness to individual
hormones in defined conditions. As shown in Figure 2D, in cul-
tured hepatocytes, the PEPCK gene is most responsive to
cAMP, which mimics activation of the glucagon receptor sig-
naling cascade, while both TAT and IGFBP-1 are induced more
effectively by glucocorticoids (dexamethasone; Figures 2E and
2F). In the absence of Foxa2, however, both the induction of
PEPCK by cAMP and the activation of TAT and IGFBP-1 by
glucocorticoids are severely blunted, explaining the reduced
activation of these genes during fasting (Figures 2D–2F). Thus,
Foxa2 is required for both cAMP and glucocorticoid signaling
in hepatocytes.142Foxa2 is nuclear in hepatocytes regardless of metabolic
state and occupies its targets constitutively
By what mechanism does Foxa2 facilitate the hormonal re-
sponse of the hepatocyte to fasting? Given the recent observa-
tions that Foxa2 can be subject to nuclear exclusion after acti-
vation of insulin signaling (Wolfrum et al., 2003, 2004), we
hypothesized that, in the fed state, Foxa2 would be localized in
the cytoplasm and therefore unable to activate its target genes.
According to this model, Foxa2-deficient hepatocytes lack a
facultative transcriptional activator, i.e., one that is only active
in the fasted state when insulin is low.
We evaluated this model in two ways. First, we utilized
immunohistochemistry with three independently derived Foxa2
antibodies to determine the localization of Foxa2 under various
metabolic conditions. As is demonstrated in Figure 3A, Foxa2
staining is clearly detectable in all hepatocyte nuclei in livers
from fasted mice. In contrast to previous findings (Wolfrum et
al., 2003, 2004), we found no evidence for nuclear exclusion of
Foxa2 immunostaining under two different conditions of ele-
vated insulin levels. In fed mice (Figure 3B) and severely insu-
lin-resistant ob/ob mice (Figure 3E), in which insulin levels were
increased more than 10-fold to 30 ng/ml, Foxa2 immuno-
staining was detected solely in the nucleus. In order to ascer-
tain the specificity of the antibody, we performed immunohisto-
chemical staining of sections from Foxa2-deficient livers inCELL METABOLISM : AUGUST 2005
Foxa2 and the hepatic fasting responseFigure 2. The transcriptional response of the hepa-
tocyte to fasting is dependent on Foxa2
Liver RNA from fed and fasted wild-type or
Foxa2loxP/loxP; AlfpCre mice was analyzed for ex-
pression of PEPCK (A), TAT (B), or IGFBP1 (C) by
quantitative RT-PCR normalized to TBP as internal
control. The normal induction of all three genes in
response to fasting is significantly blunted in the ab-
sence of Foxa2. Black bars, control mice. White
bars, Foxa2loxP/loxP; AlfpCre mice. The induction of
TAT, PEPCK, and IGFBP1 by cAMP or glucocorti-
coids in primary hepatocytes depends on Foxa2.
Primary hepatocytes were isolated from control and
Foxa2loxP/loxP; AlfpCre mice and exposed to cAMP
(the second messenger for glucagon) or dexameth-
asone (a synthetic glucocorticoid) for 16 hr before
RNA isolation and quantitative RT-PCR analysis. (D)
PEPCK is strongly induced by cAMP and to a lesser
extent by dexamethasone. The induction by cAMP
is reduced by 60% in Foxa2-deficient hepatocytes.
TAT (E) and IGFBP1 (F) mRNA levels are increased
by exposure to dexamethasone, a response that is
significantly blunted in the absence of Foxa2. Black
bars, control mice. White bars, Foxa2loxP/loxP;
AlfpCre mice. Values are represented as means plus
standard error. P values were determined by Stu-
dent’s t test.comparison to those of wild-type mice. No signal was present in
Foxa2loxP/loxP; AlfpCre mice, confirming that the anti-Foxa2 anti-
serum employed was specific for Foxa2 (Figures 3C and 3D).
In our second approach, we determined promoter and en-
hancer occupancy of Foxa2-dependent genes in the liver in vivo,
as this determines whether Foxa2 can exert its effects on the
transcriptional regulation of its targets under varying metabolic
conditions. Therefore, we isolated liver chromatin from fasted
and fed animals and assessed Foxa2 occupancy of the TAT
enhancer and PEPCK and IGFBP-1 promoters using chromatin
immunoprecipitation. Foxa2 occupied its binding sites in all
three target genes in the fasted state as expected; however,
this binding was not altered when the mice were fed and insulin
levels increased (Figure 3F). Therefore, the decreased activa-
tion of the PEPCK, TAT, and IGFBP-1 genes in Foxa2-deficient
hepatocytes that we observed solely in the fasted state (Figure
2) indicates that Foxa2 is essential to the transcriptional re-
sponse to food deprivation.
Foxa2 promotes binding of CREB and GR to their targets
in chromatin in vivo
Next, we considered the possibility that Foxa2 is required for
the expression of CREB and GR, or the potent coactivator and
metabolic regulator PGC-1α (peroxisome proliferator-activatedCELL METABOLISM : AUGUST 2005receptor-γ coactivator 1), which itself is a CREB target (Herzig
et al., 2001). However, quantitative RT-PCR demonstrated
equal mRNA levels in wild-type and mutant livers for all these
factors (data not shown).
Finally, we investigated whether Foxa2 might be required to
allow chromatin access for hormone-dependent transcription
factors that are activated during the fasting response. This no-
tion is based on the aforementioned proximity of Foxa2 binding
sites to CREs and GREs in cis-regulatory elements of several
gluconeogenic genes (Lucas and Granner, 1992; Nitsch et al.,
1993; Nitsch and Schutz, 1993; Unterman et al., 1994; Wang
et al., 1996, 1999, 2000) as well as the role of Foxa proteins as
chromatin remodeling factors during fetal hepatic development
(Cirillo et al., 2002). During differentiation of the hepatic primor-
dium from the foregut endoderm, Foxa proteins bind to en-
hancers and promoters of hepatocyte-specific genes such as
albumin even before the transcription of these target genes is
activated (McPherson et al., 1993). By altering chromatin struc-
ture, the Foxa proteins facilitate the subsequent binding of
other hepatic transcription factors (Gualdi et al., 1996). In addi-
tion, it was recently demonstrated that Foxa1 and Foxa2 coop-
erate to establish developmental competence of the foregut
endoderm to initiate the hepatogenic program (Lee et al.,
2005).143
S H O R T A R T I C L EFigure 3. Hepatocyte Foxa2 protein is nuclear irre-
spective of metabolic state and occupies promoters
and enhancers of target genes involved in the hor-
monal response to fasting
A–E) Immunohistochemical detection of Foxa2 pro-
tein using an antiserum monospecific for Foxa2.
Sections from livers from fasted (A and C), fed (B
and D), and Ob/Ob (E) mice were stained with a
rabbit polyclonal antiserum directed against Foxa2
as described in Experimental Procedures. Regard-
less of metabolic state and insulin levels, Foxa2 is
exclusively nuclear. Note that, in the Ob/Ob mouse,
insulin levels were 30 ng/ml, or 30 times higher than
in randomly fed mice. The specificity of the staining
procedure is demonstrated by the absence of signal
in Foxa2-deficient livers (C and D).
F) Immunoprecipitation of liver chromatin isolated
from fed and fasted wild-type mice with anti-Foxa2
antibodies or control IgG. Occupancy of the Foxa2
sites in the TAT enhancer and the IGFBP1 and
PEPCK promoters is not different between the fed
and fasted state. Control immunoprecipitations with
nonrelevant IgG demonstrate the specificity of the
assay. Error bars are SEM.To address the possibility that Foxa may also enable binding
of hormone-dependent transcription factors during fasting, we
performed chromatin immunoprecipitation with antibodies spe-
cific for CREB or GR on wild-type and Foxa2-deficient livers
and compared the enrichment of transcription factor binding
to the cis-regulatory elements of these gluconeogenic genes.
We focused on binding of CREB to the PEPCK promoter and
on the glucocorticoid receptor occupancy of the TAT enhancer
and IGFBP1 promoter. This choice was the result of our hepa-
tocyte experiments, in which we had observed that the ab-
sence of Foxa2 was associated with blunted induction of
PEPCK in response to cAMP, and IGFBP1 and TAT by dexa-
methasone (see Figure 2). As expected, the glucocorticoid re-
ceptor occupies the promoter of the IGFBP-1 gene and the
−2.5 kb enhancer of the TAT gene in wild-type liver, and this
binding is enhanced more than 4-fold during fasting (Figures
4A, 4C, and 4D). This increased binding of GR to its target sites
is significantly blunted in the absence of Foxa2, demonstrating
that Foxa2 is required to allow the GR full access to its targets.
We observed an equivalent requirement for Foxa2 in the case144of CREB and its target site in the PEPCK promoter. CREB bind-
ing was augmented approximately 5-fold in fasted wild-type
mice compared to fed controls, while this increase is less than
2-fold in Foxa2-deficient hepatocytes (Figures 4A and 4B), in-
dicating that Foxa2 also increases the efficacy of CREB bind-
ing to selected target sites. Given the similar biochemical char-
acteristics of the Foxa family of transcription factors and the
upregulation of Foxa1 in hepatocytes in the absence of Foxa2
demonstrated above, it appears likely that partial compensa-
tion masks an even more striking effect of Foxa2 deficiency.
Discussion
The model of regulation of Foxa2 activity by nuclear exclusion
in response to insulin signaling as proposed by Wolfrum and
colleagues (Wolfrum et al., 2003, 2004) provides a plausible
explanation to the question of how insulin exerts its well-known
effects on transcription in the liver, especially the inhibition of
expression of gluconeogenic enzymes. The model extends the
paradigm first described for the related transcription factorCELL METABOLISM : AUGUST 2005
Foxa2 and the hepatic fasting responseFigure 4. Foxa2 enables binding of CREB and GR to their binding sites in fasting responsive genes
A) Immunoprecipitation of liver chromatin isolated from fed and fasted wild-type or Foxa2loxP/loxP; AlfpCre mice with anti-CREB (for PEPCK) and anti-GR (for TAT and
IGFBP1) antibodies. Occupancy of the GREs in the TAT and IGFBP1 genes is increased in fasted wild-type mice compared to fed controls. This induction is significantly
decreased in livers deficient for Foxa2. Similarly, binding of CREB to the promoter of the PEPCK gene is increased by fasting, a response that is dependent on Foxa2.
Chromatin occupancy by CREB or GR was evaluated by quantitative PCR in chromatin from fed and fasted wild-type or Foxa2loxP/loxP; AlfpCre mice fed and fasted
wild-type or Foxa2loxP/loxP; AlfpCre mice (n = 3 for each group). Binding of CREB to the CRE in the PEPCK promoter (B), as well as binding of GR to the GREs in the
−2.5 kb enhancer in the TAT gene (C) and the IGFBP1 promoter (D), is decreased by approximately 50% in the absence of Foxa2. Black bars, control mice. White
bars, Foxa2loxP/loxP; AlfpCre mice. Values are represented as means plus standard error. P values were determined by Student’s t test.Foxo1, the mammalian ortholog of the C. elegans gene Daf16,
which had been established by genetic means to act down-
stream of the insulin receptor and protein kinase B/AKT (Lee
et al., 2001). This initial discovery was followed by others
showing that the mammalian homolog of Daf16, Foxo1, could
be phosphorylated by protein kinase B/AKT, resulting in nu-
clear exclusion and concomitant loss of transcriptional activa-
tion of its target genes (Biggs et al., 1999; Brunet et al., 1999;
Guo et al., 1999; Rena et al., 1999). In addition, the functional
significance of Foxo1 as an effector of the insulin signal trans-CELL METABOLISM : AUGUST 2005duction pathway in mammals was also explored by genetic
means. Thus, heterozygocity for Foxo1 ameliorates the dia-
betic phenotype in insulin receptor deficient mice (Nakae et
al., 2002).
However, the situation regarding Foxa2 is less clear. While
phosphorylation of Foxa2 by protein kinase B/AKT in vitro and
nuclear exclusion in hepatocytes in response to elevated insu-
lin have been reported (Wolfrum et al., 2003, 2004), our results
did not confirm these findings. Importantly, the latter study em-
ployed the same anitserum as ours (Wolfrum et al., 2004). This145
S H O R T A R T I C L Eantiserum, originally generated in the Jessell laboratory, de-
tected nuclear staining for Foxa2 in mouse embryonic tissues
(Ruiz i Altaba et al., 1993). A possible explanation for the dis-
crepancy between our results and previous studies might be
the concentration of the antiserum employed. While we utilized
the Foxa2 antiserum at a 1:2000 dilution, similar to the original
report (Ruiz i Altaba et al., 1993), Wolfrum et al. used a higher
concentration of 1:100, potentially leading to crossreactivity
with other antigens. Our results are consistent with another
study showing localization of Foxa2 exclusively in the nucleus
regardless of metabolic condition (Steneberg et al., 2005).
A further discrepancy between the data reported here and
those published by Wolfrum et al. exists regarding the targets
of Foxa2. Several genes encoding gluconeogenic enzymes
have been shown by multiple in vitro assays to be targets of
Foxa2, including the three investigated here in our in vivo
model of Foxa2 deficiency. However, Wolfrum et al. reported
that, in their chromatin immunoprecipitation assay, the pro-
moter of the PEPCK gene was not occupied by Foxa2 (Wol-
frum et al., 2004). In contrast, we detected a clear enrichment
for the PEPCK promoter in immunoprecipitation with the Foxa2
antibody (see Figure 4F). Our results are consistent with the
previous reports that identified a Foxa binding site in the
PEPCK promoter (O’Brien et al., 1995; Wang et al., 1996, 1999,
2000).
The results described above have general implications for the
computational identification of cis-regulatory elements commonly
performed to identify transcription factor “targets” using posi-
tional weight matrices derived from a relatively small number
of known targets. As shown here for the mammalian liver, the
question of whether a CRE or GRE actually functions as a bind-
ing site for its cognate transcription factor depends on the con-
text of the neighboring sequences, i.e., the presence of Foxa
binding sites, and on the cellular environment in which these
transcription factors are expressed.
In summary, we have shown that Foxa2 is required for the
activation of the hepatic transcriptional program of gluconeo-
genesis, a major evolutionary adaptation to limiting and unpre-
dictable food supply. This is achieved by integrating the re-
sponse of the hepatocyte to glucagon and glucocorticoids.
Binding of Foxa2 to its target sites allows the transcription fac-
tors CREB and GR and their potent coactivators access to cis-
regulatory elements of genes involved in the hepatic response
to fasting. The integration of the tissue-specific factor Foxa2
with the two ubiquitously expressed but hormone-dependent
activators CREB and GR assures that the gluconeogenic re-
sponse occurs only in the liver and only under the appropriate
metabolic circumstances.
Experimental procedures
Derivation of Foxa2loxP/loxP; AlfpCre mice
The derivation of the Foxa2loxP allele has been described previously (Sund
et al., 2000). To achieve hepatocyte-specific expression of Cre, we fused
the Cre coding sequence to a 2 kb fragment of the mouse albumin promoter
and a 4.6 kb fragment of the mouse α-feto protein enhancer (Hammer et
al., 1987) and obtained transgenic lines by pronuclear injection into fertilized
C57Bl/6; SJL F1 hybrid oocytes.
Immunofluorescence and immunohistochemistry
Livers were fixed in 4% PFA overnight at 4°C, embedded in paraffin, cut to
6 m sections, and applied to Probe-on Plus slides (Fisher Scientific).
Slides were deparaffinized in xylene and rehydrated through a series of146ethanol washes. Slides were subjected to microwave antigen retrieval,
washed in PBS, and blocked with protein blocking reagent (Immunotech)
for 20 min at RT. Rabbit anti-Foxa2 (K2 1:2000; a gift from Dr. T. Jessel)
was diluted in antibody diluent (Zymed) and incubated with the sections
overnight at 4°C. Slides were washed in PBS and incubated with Cy2-con-
jugated donkey anti-rabbit IgG (1:400; Jackson) for 2 hr at RT. Slides were
rinsed in PBS, mounted, and examined using confocal microscopy (Leica).
Slides subjected to immunohistochemistry were incubated in 2.25%
H2O2 for 15 min, washed in PBS, and blocked with avidin and biotin block-
ing reagents (Vector) for 15 min each at RT. Following blocking with protein
blocking reagent (Immunotech), slides were incubated overnight at 4°C with
either rabbit anti-Foxa2 (K2 1:2000; a gift from Dr. T. Jessel) or rabbit anti-
Foxa2 (1:500; a gift from Dr. J.A. Whitsett) or goat anti-Foxa2 antibody (1:50;
Santa Cruz). Slides were washed in PBS, incubated with biotinylated goat
anti-rabbit or donkey anti-goat antibody (1:200; Vector) diluted in PBT for
30 min at 37°C, washed in PBS, and incubated with HRP-conjugated ABC
reagent (Vector Elite Kit) for 30 min at 37°C. Following PBS wash, signal
was developed using DAB Substrate Kit for peroxides (Vector). Slides were
washed in water, dehydrated, mounted, and viewed using a bright-field
microscope (Nikon).
Primary hepatocyte isolation and culture
Hepatocytes were isolated from 12-week-old male mice via collagenase
(0.05% collagenase type I, Worthington) digestion and Percoll (Amersham
Biosciences AB) gradient purification and cultured in a three-dimensional
collagen matrix to maintain the differentiated state of the cells (Gomez-
Lechon et al., 1998). Freshly isolated hepatocytes were resuspended in
Ham F-12/Leibovitz-15 medium supplemented with 2% newborn calf se-
rum, 30 mM proline, 0.2% bovine serum albumin (BSA), and antibiotics.
Cellular viability was assessed by trypan blue exclusion; only preparations
with viability greater than 90% were used.
Hepatocytes were seeded in collagen type I (1.5 mg/ml) at a final density
of 0.5 × 106 cells per well. One hour after cell attachment, hepatocytes
were cultured in serum-free medium supplemented with or without 500 nM
dexamethasone (DEX, Sigma), 500 M 8-Br-cAMP (Sigma), or 100 M insu-
lin (Sigma) for 16 hr.
RNA reverse transcription and real-time PCR
Isolation of total cellular RNA from cultured hepatocytes or liver was per-
formed using the RNeasy Kit (Qiagen). RNA was quantified using the RNA
6000 Nano Assay program of the Agilent 2100 Bioanalyzer (Agilent Technol-
ogies). RNA (5 g) was reverse transcribed using 1 g oligo (dT) primer and
Superscript II Reverse Transcriptase (Invitrogen) at 42°C for 1 hr. Primers
for real-time PCR were designed using Primer3 software with a 3# bias of
NCBI mRNA sequences. PCR reaction mixes were assembled using the
Brilliant SYBR Green QPCR Master Mix (Stratagene), 10 M primers, and
the included reference dye at a 1:200 dilution. Reactions were performed
using the SYBR Green program on the Mx4000 PCR System (Stratagene).
Cycling parameters were 95°C for 10 min and 40 cycles of 95°C (30 s),
60°C (1 min), and 72°C (30 s) followed by a melting curve analysis. All reac-
tions were performed in triplicate with reference dye normalization, and the
median cycle threshold (CT) value was used for analysis. Expression levels
were normalized to those of TBP (TATA box binding protein) as internal
control. The specificity of the PCR amplification was confirmed by dissoci-
ation curve analysis. Primer sequences are available upon request.
Chromatin immunoprecipitation assay
The ChIP assay protocol was adapted from methods described previously
(Friedman et al., 2004; Weinmann et al., 2001). Mouse liver was minced in
cold PBS and passed through a 21 gauge needle. The minced tissue was
crosslinked in 1% formaldehyde/PBS for 15 min with constant shaking.
Crosslinking was quenched by the addition of glycine to a final concentra-
tion of 0.125 M. The tissue was rinsed in PBS and homogenized further
with a Dounce homogenizer. After 5 min centrifugation at 13,000 × g, the
nuclear pellet was resuspended in cell lysis buffer (5 mM PIPES [pH 8.0],
85 mM KCL, 0.5% NP40, 10 M aprotinin, 10 M leupeptin, 1 mM PMSF)
and incubated on ice for 15 min. The lysate was divided into 500 l aliquots
and sonicated using the Fisher Scientific Sonic Dismembrator Model 100
with a microtip probe and set at a power output of 4–6 W for three cycles
of 20 s each. Insoluble debris was removed by centrifugation and the super-CELL METABOLISM : AUGUST 2005
Foxa2 and the hepatic fasting responsenatant collected and flash frozen in liquid nitrogen. Quantitative PCR was
performed on the input DNA fractions to ensure that equal amounts of chro-
matin DNA were used in all immunoprecipitations. Immunoprecipitations
with anti-GR (Santa Cruz Antibody sc-1002), anti-CREB (Santa Cruz Anti-
body sc-186), and anti-Foxa2 (Khoor et al., 2004) (a kind gift from Dr. J.A.
Whitsett) or control IgG were performed as described (Friedman et al.,
2004). Immunoprecipitated DNA was then amplified by PCR with primers
specific to the promoters of the IGFBP-1 and PEPCK genes and the −2.5
kb enhancer of the TAT gene. For quantification of the relative enrichment
of the target DNA fragments in the immunoprecipitated DNA, real-time PCR
was performed using the SYBR Green as described above. Primer se-
quences are available upon request.
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